Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $7.1100 (-1.11%) ($7.0600 - $7.3100) on Fri. Mar. 29, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.09% (three month average) | RSI | 43 | Latest Price | $7.1100(-1.11%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -1.5% a day on average for past five trading days. | Weekly Trend | ADMS declines -3.1% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XOP(13%) OIH(12%) EWI(10%) XBI(10%) IBB(9%) | Factors Impacting ADMS price | ADMS will decline at least -2.545% in a week (0% probabilities). BNDX(-11%) UUP(-10%) GLD(-8%) GDX(-8%) GDXJ(-7%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.545% (StdDev 5.09%) | Hourly BBV | 0 () | Intraday Trend | -2.1% | | | |
|
1 - 5 Day Possible Target | $-24.56(-445.43%) | Resistance Level | $7.86 | 5 Day Moving Average | $7.26(-2.07%) | 10 Day Moving Average | $7.56(-5.95%) | 20 Day Moving Average | $7.86(-9.54%) | To recent high | -41.5% | To recent low | 0% | Market Cap | $201m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |